News

404

Daniel Von Hoff, M.D., F.A.C.P.

Daniel Von Hoff, M.D., F.A.C.P.

CLINICAL DEVELOPMENT

Dr. Von Hoff has conducted clinical trials on more than 200 antineoplastic and biologic agents including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, pexidartinib and others.

From 2004-2010, he served in President Bush’s National Cancer Advisory Board. He was formerly president of the American Association for Cancer Research and currently serves as Distinguished Professor and Executive Vice President of the Translational Genomics Research Institute where he concentrates on the development of molecular targeted therapies for pancreatic and other advanced cancers.

CLINICAL DEVELOPMENT

Dr. Von Hoff has conducted clinical trials on more than 200 antineoplastic and biologic agents including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, pexidartinib and others.

From 2004-2010, he served in President Bush’s National Cancer Advisory Board. He was formerly president of the American Association for Cancer Research and currently serves as Distinguished Professor and Executive Vice President of the Translational Genomics Research Institute where he concentrates on the development of molecular targeted therapies for pancreatic and other advanced cancers.

Scroll to top